Pharmacologic Treatment with GABA<sub>B</sub> Receptor Agonist of Methamphetamine-Induced Cognitive Impairment in Mice

Hiroyuki Mizoguchi<sup>1,2</sup> and Kiyofumi Yamada<sup>2,3,*</sup>

<sup>1</sup>Futuristic Environmental Simulation Center, Research Institute of Environmental Medicine, Nagoya University, Nagoya 464-8601, Japan; <sup>2</sup>Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Japan; <sup>3</sup>JST, CREST, Japan

Abstract: Methamphetamine (METH) is a highly addictive drug, and addiction to METH has increased to epidemic proportions worldwide. Chronic use of METH causes psychiatric symptoms, such as hallucinations and delusions, and long-term cognitive deficits, which are indistinguishable from paranoid schizophrenia. The GABA receptor system is known to play a significant role in modulating the dopaminergic neuronal system, which is related to behavioral changes induced by drug abuse. However, few studies have investigated the effects of GABA receptor agonists on cognitive deficits induced by METH. In the present review, we show that baclofen, a GABA receptor agonist, is effective in treating METH-induced impairment of object recognition memory and prepulse inhibition (PPI) of the startle reflex, a measure of sensorimotor gating in mice. Acute and repeated treatment with METH induced a significant impairment of PPI. Furthermore, repeated but not acute treatment of METH resulted in a long-lasting deficit of object recognition memory. Baclofen, a GABA<sub>B</sub> receptor agonist, dose-dependently ameliorated the METH-induced PPI deficits and object recognition memory impairment in mice. On the other hand, THIP, a GABA<sub>A</sub> receptor agonist, had no effect on METH-induced cognitive deficits. These results suggest that GABA<sub>B</sub> receptors may constitute a putative new target in treating cognitive deficits in chronic METH users.

Keywords: Baclofen, methamphetamine, cognition, prepulse inhibition, GABA<sub>B</sub> receptor.

METHAMPHETAMINE-INDUCED COGNITIVE IMPAIRMENT

Methamphetamine (METH) increases the amount of dopamine released in synapses by reversing the function of the dopamine transporter, which is associated with the rewarding effects of the drug [1-4]. Chronic use of METH leads to addiction (dependence) and long-lasting impairment of brain function with hallucinations and delusions, which are indistinguishable from paranoid schizophrenia [5, 6]. Furthermore, chronic METH users show significantly poorer performances on measures of attention/psychomotor speed, verbal learning and memory, and executive function, demonstrating that METH dependence is associated with impairments across a range of neurocognitive domains [7].

Numerous studies indicate that METH disrupts neurotransmitter function and in particular the dopaminergic system, although changes in serotonergic, noradrenergic, and glutamatergic functions are also observed [5, 8, 9]. It has been argued that these neuropathological changes underpin the neurocognitive deficits associated with METH use in humans [5]. Consistent with this possibility, in a recent meta-analysis of the neurocognitive effects of METH, Scott et al. [10] reported significant impairment in several cognitive domains that are considered to affect the integrity of these neural substrates, including retrospective memory, information processing speed, and executive operations such as inhibitory control.

In order to understand the etiology of METH-induced cognitive impairment in chronic METH users, it is necessary to establish animal models. Therefore, we investigated the effect of METH on learning and memory as well as sensorimotor gating in rodents. We demonstrated that repeated METH treatment of mice followed by withdrawal impairs long-term recognition memory, without affecting learning or short-term memory, and that METH-induced cognitive impairment is reversed by an atypical antipsychotic, clozapine, but not by haloperidol [11]. Moreover, we have demonstrated that repeated METH treatment in rats impairs working memory in a delayed spatial win-shift task using a radial arm maze and that clozapine, but not haloperidol, is effective in improving the METH-induced working memory deficit [12]. Because clinical evidence has shown that clozapine is superior to typical therapeutics such as haloperidol in improving cognitive deficits in schizophrenic patients [13, 14], the METH-induced cognitive impairment in rodents may be useful as an animal model for cognitive deficits in METH abusers as well as schizophrenic patients, in which cognitive deficits are regarded as a core feature.

Our recent studies indicated that activation of the ERK1/2 signaling pathway, which is associated with the dopamine D1 receptor [15, 16], plays an important role in memory function under physiological and pathological conditions [11, 17-19]. We have also proposed that impairment of the dopamine D1 receptor-ERK1/2 signaling pathway in the prefrontal cortex (PFC) is involved in METH-induced...
deficits of recognition memory [11, 20], and that ERK1/2 activation is related to the performance in working memory [19]. On the basis of our findings, Ito et al. [17] and Mizoguchi et al. [21] showed that ZSET1446, a novel azaindolizine derivative, or minocycline ameliorated METH-induced cognitive impairment through, at least in part, activation of the ERK1/2 pathway in the PFC linked to dopamine D1 receptors.

GABA RECEPTOR

The GABA receptor system is known to play a significant role in modulating the dopamine system [22]. Baclofen, a GABA_B receptor agonist, is known to stabilize the firing pattern of dopamine neurons [23]. Baclofen has been shown to attenuate amphetamine-induced increase in dopamine levels in the nucleus accumbens [24], and GABA_A receptors on dopamine neurons in the ventral tegmental area play a significant role in attenuating the effects of drug abuse in a similar manner to that of GABA_B receptors [25]. Therefore, several studies have demonstrated that GABA receptor agonists can inhibit the effects of drug abuse. For example, previous studies showed that baclofen reduced the reinforcing effects of many substances of abuse, such as cocaine, nicotine, heroin, and alcohol [26], possibly through GABA_A-mediated modulation of mesolimbic dopamine transmission [27]. It was demonstrated that chronic coadministration of baclofen and amphetamine blocked the development of sensitization to the locomotor stimulation effect of amphetamine [28], and acute treatment with baclofen inhibited the expression of amphetamine-induced locomotor sensitization [29]. Moreover, a recent study showed that acute treatment with baclofen ameliorated ethanol-induced memory deficit in mice [30].

Clinical studies have shown significant haplotype associations between different genes and METH use or the development of METH-induced psychosis. In particular, several case-control association studies suggest that the human GABA_A receptor γ2 subunit gene is marginally associated with METH use disorder and may be one of the susceptibility genes of METH use disorder [31, 32]. Moreover, several clinical studies have demonstrated that GABA agonists including topiramate, baclofen and GABA transaminase inhibitor show promise in reducing the METH use/craving [33]. Thus, in many studies, the effects of GABA receptor agonists on hyperdopaminergic conditions induced by psychostimulant drugs have been examined; however, few studies have involved investigation of the effects of GABA receptor agonists on cognitive deficits induced by drugs abuse. In the following sections, we discuss the effects of GABA receptor agonists on METH-induced cognitive impairment.

EFFECTS OF GABA RECEPTOR AGONISTS ON METH-INDUCED IMPAIRMENT OF RECOGNITION MEMORY

As described above, repeated treatment with METH (1 mg/kg, s.c.) for 7 days impairs object recognition memory in mice in a novel objective recognition test, which is associated with dysfunction of the dopamine D1 receptor-ERK1/2 pathway in the prefrontal cortex [11]. To develop novel pharmacotherapy for cognitive deficits in METH abusers, we examined the effects of GABA_A and GABA_B receptor agonists in this animal model.

We found that acute treatment with baclofen (1-2 mg/kg) improved METH-induced cognitive deficit without affecting motor function. In contrast, gaboxadol (1-3 mg/kg), a GABA_A receptor agonist, had no effect on METH-induced cognitive deficits. These results suggest that GABA_A receptor agonists may be useful for the treatment of cognitive deficit in METH abusers (Table 1) [34]. Although further studies are necessary to clarify the molecular mechanisms of the action of baclofen, its ameliorating effect on METH-induced cognitive deficit may be, at least in part, due to the inhibitory effect on METH-evoked hyperphosphorylation of ERK1/2 in the PFC. Alternatively, a previous study demonstrated that activation of GABA_A receptors led to an increase in ERK1/2 phosphorylation in the CA1 area of mouse hippocampal slices and promoted CREB2-mediated transcription through an ERK-dependent mechanism, suggesting that GABA_A receptor antagonists may play a crucial role in regulating synaptic facilitation and memory through regulating protein synthesis and gene expression [35].

Table 1. Effects of GABA Receptor Agonist on Methamphetamine-Induced Cognitive Dysfunction in Mice

| Methamphetamine-Induced Cognitive Impairment | Recognition Memory | Sensorimotor Gating* |
|---------------------------------------------|--------------------|----------------------|
| Baclofen                                     | ↑                  | ↑                    |
| Gaboxadol                                    | •                  | N.D.                 |

↑: improvement; •: no effect; N.D.: not detected.

*Sensorimotor gating was assessed by the PPI of the acoustic startle reflex.

EFFECTS OF GABA RECEPTOR AGONISTS ON METH-INDUCED DISRUPTION OF PREPULSE INHIBITION

Prepulse inhibition (PPI) of the startle reflex is viewed as a measure of a process called ‘sensorimotor gating’. Deficits in PPI are observed in patients suffering from certain psychiatric disorders such as schizophrenia [36, 37]. We have previously demonstrated that GABAergic neurons in the lateral globus pallidus (LGP), which project directly towards the pedunculopontine tegmental neurons (PPTg), are activated by prepulse stimuli but not by startle pulse stimuli and play an important role in PPI [38]. It is suggested that the pallidodemental GABAergic neurons act as an interface between the brainstem PPI-mediating and the forebrain PPI-regulating circuits by using c-Fos, a neural activation marker, immunohistochemistry. Moreover, we demonstrated that the disruption of PPI caused by METH was accompanied by impairment of the LGP and hyperactivation of the caudal pontine reticular nucleus (PnC), which manifested as changes in c-Fos expression in the LGP and PnC after the PPI test; therefore, it is reasonable to assume that METH disrupts PPI of the startle reflex in mice by inhibiting the activation of pallidotegmental GABAergic neurons evoked by a prepulse stimulus [39].
Pharmacologic Treatment with GABA Receptor

Baclofen (1-5 mg/kg) dose-dependently ameliorated PPI impairment induced by acute treatment with METH (3 mg/kg) (Table 1), which was associated with the reversal of METH-induced decrease in c-Fos expression in LGP, and METH-induced increase in c-Fos expression in PnC. Consistent with our findings, it was reported that baclofen reversed the reduction in PPI induced by MK-801, but not that by apomorphine (a direct dopamine receptor agonist), in rats [40], and that baclofen and clozapine, but not haloperidol, improved spontaneous PPI deficit in mice [41].

CONCLUSION

In conclusion, baclofen acutely ameliorated the cognitive deficits in repeated METH-treated mice, an animal model for METH-induced increase in c-Fos expression in PnC. Consistent with our findings, it was reported that baclofen reversed the reduction in PPI induced by MK-801, but not that by apomorphine (a direct dopamine receptor agonist), in rats [40], and that baclofen and clozapine, but not haloperidol, improved spontaneous PPI deficit in mice [41].

ACKNOWLEDGMENTS

This study was supported in part by a Grant-in-aid for Scientific Research (No.19390062) from the Japan Society for the Promotion of Science and by grants for the global COE program from the Ministry of Education, Culture, Sports, Science and Technology of Japan, the Academic Frontier Project for Private Universities; matching fund subsidy from MEXT, 2007-2011, the Research on the Risk of Chemical Substances, Health and Labour Science Research Grants supported by the Ministry of Health, Labour and Welfare, the Regional Joint Research Program supported by grants to Private Universities to Cover Current Expenses from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), and JST, CREST.

REFERENCES

[1] Mizoguchi, H.; Yamada, K.; Nabeshima, T. Neuropharmacological effects of abused drugs: involvement of matrix metalloproteinase-2 and -9 and tissue inhibitor of matrix metalloproteinase-2 in methamphetamine-induced behavioral sensitization and reward in rodents. J. Pharmacol. Sci., 2008, 106, 9-14.

[2] Mizoguchi, H.; Yamada, K.; Niwa, M.; Mouru, A.; Mizuno, T.; Noda, Y.; Nitta, A.; Iohara, S.; Banno, Y.; Nabeshima, T. Reduction of methamphetamine-induced sensitization and reward in matrix metalloproteinase-2 and -9-deficient mice. J. Neurochem., 2007, 100, 1579-1588.

[3] Nakajima, A.; Yamada, K.; Nagai, T.; Uchiyama, T.; Miyamoto, Y.; Mamiya, T.; He, J.; Nitta, A.; Mizuno, M.; Tran, M.H.; Seto, A.; Yoshimura, M.; Kitaiishi, K.; Hasegawa, T.; Saito, K.; Yamada, Y.; Seishima, M.; Sekikawa, K.; Kim, H.C.; Nabeshima, T. Role of tumor necrosis factor-a in methamphetamine-induced drug dependence and neurotoxicity. J. Neurosci., 2004, 24, 2212-2225.

[4] Yamada, K. Endogenous modulators for drug dependence. Biol. Pharm. Bull., 2008, 31, 1635-1638.

[5] Nordahl, T.E.; Sato, R.; Leamon, M. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: A review. J. Neuropsychiatry. Clin. Neurosci., 2003, 15, 317-325.

[6] Simon, S.L.; Domier, C.; Brethen, P.; Rawson, R.; Ling, W. Cognitive impairment in individuals currently using methamphetamine. Am. J. Addict., 2000, 9, 222-231.

[7] Kalezstein, A.D.; Newton, T.F.; Green, M. Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. J. Neuropsychiatry Clin. Neurosci., 2003, 15, 215-220.

[8] Meredith, C.W.; Jaffe, C.; Ang-Lee, K.; Saxson, A.J. Implications of chronic methamphetamine use: a literature review. Harv. Rev. Psychiatry, 2005, 13, 141-154.

[9] Mizoguchi, H.; Yamada, K.; Mouru, A.; Niwa, M.; Mizuno, T.; Noda, Y.; Nitta, A.; Iohara, S.; Banno, Y.; Nabeshima T. Role of matrix metalloproteinase-2 and tissue inhibitor of MMMP in methamphetamine-induced behavioral sensitization and reward: implications for dopamine receptor down-regulation and dopamine release. J. Neurochem., 2007, 102, 1548-1560.

[10] Scott, J.C.; Woods, S.P.; Matt, G.E.; Meyer, R.A.; Heaton, R.K.; Atkinson, J.H.; Grant, I. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol. Rev., 2007, 17, 275-297.

[11] Kamei, H.; Nagai, T.; Nakano, H.; Togan, Y.; Takayanagi, M.; Takahashi, K.; Kobayashi, K.; Yoshida, S.; Maeda, K.; Takuma, K.; Nabeshima, T.; Yamada, K. Repeated methamphetamine treatment impairs recognition memory through a failure of novelty-induced ERK 1/2 activation in the prefrontal cortex of mice. Biol. Psychiatry, 2006, 59, 75-84.

[12] Nagai, T.; Takuma, K.; Dohiwa, M.; Ibi, D.; Mizoguchi, H.; Kamei, H.; Nabeshima, T.; Yamada, K. Repeated methamphetamine treatment impairs spatial working memory in rats: reversal by clozapine but not haloperidol. Psychopharmacology (Berl), 2007, 194, 21-32.

[13] Meltzer, H.Y.; McGurk, S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull., 1999, 25, 233-255.

[14] Woodward, N.D.; Purdon, S.E.; Meltzer, H.Y.; Zald, D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol., 2005, 8, 457-472.

[15] Valjent, E.; Corvol, J.C.; Pages, C.; Besson, M.J.; Maldonado, R.; Caboche, J. Involvement of the extracellular signal-regulated kinase cascade for cocaine-rewarding properties. J. Neurosci., 2000, 20, 8701-8709.

[16] Zanassi, P.; Paolillo, M.; Feliciello, A.; Avvedimento, E.V.; Gallo, V.; Schinelli, S. cAMP-dependent protein kinase induces cAMP-response element-binding protein protein phosphorylation via an intracellular calcium release/ERK-dependent pathway in striatal neurons. J. Biol. Chem., 2001, 276, 11487-11495.

[17] Ito, Y.; Takuma, K.; Mizoguchi, H.; Nagai, T.; Yamada, K. A novel azaindolizidione derivative ZSET1446 (spiro[imidazo][1,2-a]pyridine-3,2-indan]-2(H)-one) improves methamphetamine-induced impairment of recognition memory in mice by activating extracellular signal-regulated kinase 1/2. J. Pharmacol. Exp. Ther., 2007, 320, 819-827.

[18] Mizoguchi, H.; Yamada, K.; Mizuno, M.; Mizuno, T.; Nitta, A.; Noda, Y.; Nabeshima, T. Regulations of methamphetamine reward by extracellular signal-regulated kinase 1/2/ets-like gene-1 signaling pathway via the activation of dopamine receptors. Mol. Pharmacol., 2004, 65, 1293-1301.

[19] Nagai, T.; Kamei, H.; Dohiwa, M.; Takayanagi, M.; Suzuki, M.; Matsuya, T.; Nabeshima, T.; Takuma, K.; Yamada, K. Involvement of hippocampal extracellular signal-regulated kinase 1/2 in spatial working memory in rats. Neuroreport, 2006, 17, 1453-1457.

[20] Nagai, T.; Takuma, K.; Kamei, H.; Ito, Y.; Nakamichi, N.; Ibi, D.; Nakashibi, Y.; Murali M.; Mizoguchi, H.; Nabeshima, T.; Yamada, K. Dopamine D1 receptors regulate protein synthesis-dependent long-term recognition memory via extracellular signal-regulated kinase 1/2 in the prefrontal cortex. Learn. Mem., 2007, 14, 117-125.

[21] Mizoguchi, H.; Takuma, K.; Fukakusa, A.; Ito, Y.; Nakatani, A.; Ibi, D.; Kim, H.C.; Yamada, K. Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice. Psychopharmacology (Berl), 2008, 196, 233-241.

[22] Tepper, J.M.; Lee, C.R. GABAergic control of substantia nigra dopaminergic neurons. Prog. Brain. Res., 2007, 160, 189-208.

[23] Erhardt, S.; Mathe, I.M.; Chergui, K.; Engberg, G.; Svensson, T.H. GABAa receptor-mediated modulation of the firing pattern of ventral tegmental area dopamine neurons in vivo. Naunyn-Schmiedebergs Arch. Pharmacol., 2002, 365, 173-180.

[24] Brebner, K.; Ahn, S.; Phillips, A.G. Attenuation of d-amphetamine self-administration by baclofen in the rat: behavioral and neurochemical correlates. Psychopharmacology (Berl), 2005, 177, 409-417.
Westerink, B.H.; Kwint, H.F.; deVries, J.B. The pharmacology of mesolimbic dopamine neurons: a dual-probe microdialysis study in the ventral tegmental area and nucleus accumbens of the rat brain. J. Neurosci., 1996, 16, 2605-2611.

Cousins, M.S.; Roberts, D.C.; De, Wit. H. GABA<sub>B</sub> receptor agonists for the treatment of drug addiction: a review of recent findings. Drug Alcohol Depend., 2002, 65, 209-220.

Bartholini, G. GABA receptor agonists: pharmacological spectrum and therapeutic action. Med. Res. Rev., 1985, 5, 55-75.

Bartoletti, M.; Gubellini, C.; Ricci, F.; Gaiardi, M. Baclofen blocks the development of sensitization to the locomotor stimulant effect of amphetamine. Behav. Pharmacol., 2005, 16, 2605-2611.

Escher, T.; Mittleman, G. Effects of ethanol and GABA<sub>B</sub> drugs on working memory in C57BL/6J and DBA/2J mice. Psychopharmacology (Berl), 2004, 176, 166-174.

Lin, S.K.; Chen, C.K.; Ball, D.; Liu, H.C.; Loh, E.W. Gender-specific contribution of the GABA<sub>B</sub> subunit genes on 5q33 in methamphetamine use disorder. Pharmacogenomics J., 2003, 3, 349-355.

Nishiyama, T.; Ikeda, M.; Iwata, N.; Suzuki, T.; Kitajima, T.; Yamashita, Y.; Sekine, Y.; Iyo, M.; Harano, M.; Komiya, T.; Yamada, M.; Sora, I.; Ujike, H.; Inada, T.; Furukawa, T.; Ozaki, N. Haplotype association between GABA<sub>A</sub> receptor gamma2 subunit gene (GABRG2) and methamphetamine use disorder. Pharmacogenomics J., 2005, 5, 89-95.

Rose, M.E.; Grant J.E. Pharmacotherapy for methamphetamine dependence: a review of the pathophysiology of methamphetamine addiction and the theoretical basis and efficacy of pharmacotherapeutic interventions. Ann. Clin. Psychiatry, 2008, 20, 145-155.

Arai, S.; Takuma, K.; Mizoguchi, H.; Ibi, D.; Nagai, T.; Kamei, H.; Kim, H.C.; Yamada, K. GABA<sub>B</sub> receptor agonist baclofen improves methamphetamine-induced cognitive deficit in mice. Eur. J. Pharmacol., 2009, 602, 101-104.

Vanhoose, A.M.; Emery, M.; Jimenez, L.; Winder, D.G. ERK activation by G-protein-coupled receptors in mouse brain is receptor identity-specific. J. Biol. Chem., 2002, 277, 9049-9053.

Castellanos, F.X.; Fine, E.J.; Kaysen, D.L.; Kozuch, P.L.; Hamburger, S.D.; Rapoport, J.L.; Hallett, M. Sensorimotor gating in boys with Tourette’s syndrome and ADHD. Biol. Psychiatry, 1996, 39, 33-41.

Swerdlow, N.R.; Braff, D.L.; Taaid, N.; Geyer, M.A. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch. Gen. Psychiatry, 1994, 51, 139-154.

Takahashi, K.; Nagai, T.; Kamei, H.; Maeda, K.; Matsuya, T.; Arai, S.; Mizoguchi, H.; Yoneda, Y.; Nabeshima, T.; Takuma, K.; Yamada, K. Neural circuits containing pallidodentatal GABAergic neurons are involved in the prepulse inhibition of the startle reflex in mice. Biol. Psychiatry, 2007, 62, 148-157.

Arai, S.; Takuma, K.; Mizoguchi, H.; Ibi, D.; Nagai, T.; Takahashi, K.; Kamei, H.; Nabeshima, T.; Yamada, K. Involvement of pallido-dentatal neurons in methamphetamine- and MK-801-Induced impairment of prepulse inhibition of the acoustic startle reflex in mice: reversal by GABA<sub>B</sub> receptor agonist baclofen. Neuropsychopharmacology, 2008, 33, 3164-3175.

Bortolato, M.; Fluhr, R.; Arai, G.; Mazzoni, M.; Gessa, G.L. Baclofen reverses the reduction in prepulse inhibition of the acoustic startle response induced by dizocilpine, but not by apomorphine. Psychopharmacology (Berl), 2004, 171, 322-330.

Bortolato, M.; Fluhr, R.; Mazzoni, M.; Piras, A.P.; Fà, M.; Tuveri, A.; Puligheddu, M.; Gessa, G.L.; Castelli, M.P.; Moreu, G.; Marrosu, F. Activation of GABA<sub>B</sub> receptors reverses spontaneous gating deficits in juvenile DBA/2J mice. Psychopharmacology (Berl), 2007, 194, 361-369.